COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PRION-1: Quinacrine for Human Prion Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00104663
Recruitment Status : Completed
First Posted : March 4, 2005
Last Update Posted : April 7, 2015
Information provided by:
Medical Research Council

Brief Summary:
PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therapeutic options for human prion disease that can be refined or expanded in the future, as new agents become available.

Condition or disease Intervention/treatment Phase
Prion Disease Drug: Quinacrine Not Applicable

Detailed Description:

The human prion diseases have been traditionally classified into Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) disease and kuru. They can alternatively be classified into three causal categories: sporadic, acquired and inherited. The appearance of a new human prion disease, variant CJD (vCJD), in the United Kingdom from 1995 onwards, and the experimental evidence that this is caused by the same prion strain as that causing bovine spongiform encephalopathy (BSE) in cattle, has raised the possibility that a major epidemic of vCJD will occur in the United Kingdom and other countries as a result of dietary or other exposure to BSE prions. These concerns have led to intensified efforts to develop therapeutic interventions.

Quinacrine has been previously used to treat other diseases such as malaria; however, it was found to have serious side effects and is no longer licensed in the United Kingdom. There is only very limited evidence from laboratory tests for the potential use of quinacrine in human prion disease, and the evidence to date for any possible clinical benefit is very scarce. The PRION-1 trial is being undertaken since there are no other drugs currently available which are considered suitable for human evaluation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 160 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PRION-1: Quinacrine for Human Prion Disease. A Partially Randomized Patient Preference Trial to Evaluate the Activity and Safety of Quinacrine in Human Prion Disease
Study Start Date : June 2004
Study Completion Date : March 2007

Primary Outcome Measures :
  1. Time to death
  2. proportion of responders, with "responders" defined as patients showing either clinical improvement or lack of deterioration in 3 key neurological and neuropsychiatric measures

Secondary Outcome Measures :
  1. Mini Mental State Examination (MMSE)
  2. Clinician's Dementia rating (CDR)
  3. Rankin score
  4. Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
  5. Glasgow coma score
  6. Barthel Activities of Daily Living (ADL)
  7. magnetic resonance imaging scan (MRI)
  8. electro-encephalogram (EEG)
  9. cerebrospinal fluid (CSF)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 12 years or more, diagnosed with any type of human prion disease.

Exclusion Criteria:

  • In a coma, or in a pre-terminal phase of disease such that prolongation of the current quality of life would not be supported
  • Known sensitivity to quinacrine
  • Been taking any other putative anti-prion therapy for less than 8 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00104663

Layout table for location information
United Kingdom
National Prion Clinic
London, United Kingdom, WC1N 3BG
Sponsors and Collaborators
Medical Research Council
Layout table for investigator information
Principal Investigator: John Collinge, MD, FRCP MRC Prion Unit
Study Director: Janet Darbyshire, MBChB, FRCP MRC Clinical Trials Unit
Additional Information:
Layout table for additonal information Identifier: NCT00104663    
Other Study ID Numbers: Version 1.1
Grant ID:71361
First Posted: March 4, 2005    Key Record Dates
Last Update Posted: April 7, 2015
Last Verified: April 2015
Keywords provided by Medical Research Council:
Creutzfeldt-Jakob disease
new variant CJD
Additional relevant MeSH terms:
Layout table for MeSH terms
Prion Diseases
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Anticestodal Agents
Antiplatyhelmintic Agents
Antiparasitic Agents
Anti-Infective Agents
Antiprotozoal Agents
Antinematodal Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action